Biogen-2026-JPM.pdf

1、DELIVERING THE NEW BIOGEN:DELIVERING THE NEW BIOGEN:THE NEXT CHAPTER OF THE NEXT CHAPTER OF INNOVATION AND GROWTHINNOVATION AND GROWTHJanuary 12,2026 CHRISTOPHER A.VIEHBACHERCHRISTOPHER A.VIEHBACHERPRESIDENT AND CHIEF EXECUTIVE OFFICERThis presentation and discussions during this webcast contain for

2、ward-looking statements,relating to:our strategy and plans;potential of,and expectations for,our commercial business and pipeline programs;capital allocation and investment strategy;clinical development programs,clinical trials,and data readouts and presentations;regulatory discussions,submissions,f

3、ilings,and approvals;the potential benefits,safety,and efficacy of our and our collaboration partners products and investigational therapies;the anticipated benefits and potential of investments or acquisitions;optimization of our cost structure including our Fit for Growth program;the goal of creat

4、ing long-term sustainable growth;the impact from potential tariffs;productivity of our R&D pipeline,collaborations,and business development activities;our future financial and operating results;and our full year 2025 financial guidance.These forward-looking statements may be accompanied by such word

5、s as“aim,”“anticipate,”“assume,”“believe,”“contemplate,”“continue,”“could,”“estimate,”“expect,”“forecast,”“goal,”“guidance,”“hope,”“intend,”“may,”“objective,”“outlook,”“plan,”“possible,”“potential,”“predict,”“project,”“prospect,”“should,”“target,”“will,”“would,”and other words and terms of similar m

6、eaning.Drug development and commercialization involve a high degree of risk,and only a small number of research and development programs result in commercialization of a product.Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale c